Doxepin Therapeutic Cheat Sheet
As dermatologists, pruritus (or itch) is one of the most frequent symptoms that we encounter. The broad spectrum of itch severity in patients with various dermatologic conditions suggests a need for a host of “tools” or medications that dermatologists should have in their toolbox. In this publication, we continue our Therapeutic Cheat Sheet series by highlighting the uses of Doxepin in dermato …
As dermatologists, pruritus (or itch) is one of the most frequent symptoms that we encounter. The broad spectrum of itch severity in patients with various dermatologic conditions suggests a need for a host of “tools” or medications that dermatologists should have in their toolbox. In this publication, we continue our Therapeutic Cheat Sheet series by highlighting the uses of Doxepin in dermato … 
Next Steps in Derm and the Journal of Drugs in Dermatology, in partnership with the Dermatology Education Foundation (DEF) and Physicians Resources, interviewed Dr. April Armstrong (Professor of Dermatology and Associate Dean for Clinical Research at the Keck School of Medicine at USC) on applying the psoriasis guidelines established by the American Academy of Dermatology and the National Psor … 
Patients with skin of color are at significantly higher risk of developing keloid scars compared with their fair-skinned counterparts. At the 2022 Skin of Color Update, Dr. Eva Kerby, Assistant Dermatology Professor at Weill Cornell Medicine, and Dr. Maritza Perez, Professor of Dermatology at the University of Connecticut, shared their pathogenesis-informed medical and procedural treatment strat … 
A patient comes in with the rash pictured below consisting of pustules in an annular or polycyclic configuration. What type of paraproteinemia can this disorder be associated with and thus a workup should be initiated for?
A. IgG kappa
B. IgG lambda
C. IgA
D. IgM
E. IgD
To find out the correct answer and read the explanation, click here.
Brought to you by our brand … 
INTRODUCTION
Tofacitinib is a Janus kinase (JAK) 1-3 inhibitor first U.S. Food and Drug Administration (FDA) approved in 2012 for rheumatoid arthritis, with subsequent approval for psoriatic arthritis, ulcerative colitis, polyarticular course juvenile idiopathic arthritis, and ankylosing spondylitis in 2017, 2018, 2020, and 2021, respectively.1,2 In the last several years, oral tofacitinib …